SLC13A5

Na(+)/citrate cotransporter · Q86YT5 · SLC13A5 on Sugi Atlas →

9,362 patent compounds predicted against SLC13A5, 5,691 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL614651	0.57	14/20
SCHEMBL614652	0.57	14/20
Citric Acid (SCHEMBL1666464)	0.44	12/20
Citric Acid (SCHEMBL1666467)	0.44	12/20
SCHEMBL1333057	0.47	10/20
Alpha-Ketoglutaric Acid (SCHEMBL1498891)	0.39	10/20
Propene (SCHEMBL424592)	0.36	10/20
SCHEMBL1270966	0.35	10/20
SCHEMBL120587	0.33	10/20
Citric Acid (SCHEMBL105545)	0.38	9/20
Citric Acid (SCHEMBL108968)	0.38	9/20
Citric Acid (SCHEMBL1508886)	0.38	9/20
SCHEMBL324871	0.37	9/20
Citric Acid (SCHEMBL667369)	0.37	9/20
Acetic Acid (SCHEMBL1240745)	0.35	9/20
Citric Acid (SCHEMBL1323383)	0.33	9/20
SCHEMBL111251	0.46	8/20
SCHEMBL258974	0.46	8/20
Citric Acid (SCHEMBL94288)	0.41	8/20
Citric Acid (SCHEMBL125278)	0.41	8/20

Clinical trials — most relevant to SLC13A5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)	PHASE4	COMPLETED
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder	PHASE1/PHASE2	NOT_YET_RECRUITING
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops	PHASE2	UNKNOWN
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC	PHASE1	COMPLETED
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
SLC13A5 Deficiency Natural History Study - United States Only	nan	ENROLLING_BY_INVITATION
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Sodium Transport: Genetics and Hypertension	nan	COMPLETED
Oxalate and Citrate	nan	RECRUITING
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Lithium Countertransport and Blood Pressure In CARDIA and TOMHS	nan	COMPLETED
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital	nan	UNKNOWN
Renal Transporters After Renal Transplantation	nan	UNKNOWN
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy	nan	COMPLETED
Effect of SLC01B1 (rs4149956) Polymorphism on the Efficacy and Tolerability of Atorvastatin in Pakistani Population	nan	COMPLETED
Genetic Variants and Iron Absorption	nan	COMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS	nan	NOT_YET_RECRUITING
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Epidemiology of Gout in French Polynesia	nan	COMPLETED
Identification and Characterization of Monogenic Diabetes	nan	COMPLETED
Gyrate Atrophy Ocular and Systemic Study	nan	ACTIVE_NOT_RECRUITING
Genetic Variations That Increase the Risk for Calcium Kidney Stones: a Family-based Study	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC13A5 binder may also engage these)

Protein	Name	Similarity
Q67BT3	—	0.997	Q67BT3 →
Q9ES88	—	0.989	Q9ES88 →
Q8CJ44	—	0.989	Q8CJ44 →
P70545	—	0.988	P70545 →
Q9JHI4	—	0.987	Q9JHI4 →
SLC13A2	Solute carrier family 13 member 2	0.987	landscape →
Q91Y63	—	0.987	Q91Y63 →
Q28615	—	0.986	Q28615 →
Q07782	—	0.984	Q07782 →
Q9BZW2	—	0.982	Q9BZW2 →
Q9Z0Z5	—	0.981	Q9Z0Z5 →
SLC13A3	Na(+)/dicarboxylate cotransporter 3	0.978	landscape →
Q9UKG4	—	0.974	Q9UKG4 →
Q93655	—	0.971	Q93655 →
Q21339	—	0.970	Q21339 →
Q9VVT2	—	0.968	Q9VVT2 →
P46556	—	0.964	P46556 →
P58743	—	0.961	P58743 →
Q25605	—	0.957	Q25605 →
Q9JKQ2	—	0.957	Q9JKQ2 →
SLC1A1	Excitatory amino acid transporter 3	0.956	landscape →
Q8LG88	—	0.956	Q8LG88 →
P31597	—	0.955	P31597 →
Q10901	—	0.955	Q10901 →
Q9EPH0	—	0.955	Q9EPH0 →
Q5SWY8	—	0.954	Q5SWY8 →
Q3ZMH1	—	0.954	Q3ZMH1 →
Q99NH7	—	0.954	Q99NH7 →
A0PJK1	—	0.954	A0PJK1 →
SLC5A11	Sodium/myo-inositol cotransporter 2	0.954	landscape →